Answers are grounded in this paper and cite their sources.
Aims Published poison-center tables may use different counting units, denominators, and medication definitions, limiting their reuse. We appraised the availability and comparability of National Poison Center (UZEM) medication-group data and described analgesic and separately classified anti-inflammatory/antirheumatic records. Methods This retrospective reporting appraisal and descriptive secondary analysis used the 728-page public 2014-2020 UZEM compendium. Eligible tables contained target-group records, related agents, age strata, or required denominators. Seven study-specific domains guided comparison decisions: temporal availability, denominators, agent definitions, repeated reporting, numerical consistency, clinical linkage, and coding changes. Primary descriptive measures were annual group counts and all-case percentages for 2018-2020, calculated using explicit same-year denominators. Published entries and arithmetic were verified against source tables. Repeated table entries were excluded from summation; incompatible agent definitions remained separate. No hypothesis testing was performed. Results Twenty-four core tables were included; five repeated full-distribution counts in top lists. Individual ages and target-group sex distributions were unavailable. For 2018, 2019, and 2020, analgesic counts were 13,423 (6.18%), 13,744 (6.31%), and 10,619 (5.66%); anti-inflammatory/antirheumatic counts were 20,560 (9.46%), 23,755 (10.90%), and 18,395 (9.81%). All-case denominators were 217,323, 217,936, and 187,528, respectively. Although analgesic counts decreased by 22.74% between 2019 and 2020, their share of human-health-product records changed from 8.96% to 8.63% (denominators 153,427 and 122,995, respectively). All 96 selected label/count/percentage combinations matched the source; 84 percentages with explicit denominators and five distributions comprising 1,242 rows were verified. General target-group distributions for 2014-2017 and group-linked clinical outcomes were not identified. Agent definitions differed across years, and coding stability was undocumented. Conclusions The appraisal linked annual medication-group summaries to their source definitions and documented denominator, classification, and clinical-linkage constraints on secondary use of the published compendium.
No takes yet. Share an insight, caveat, or question.
Yıldırım Cesaretli (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: